Recent studies, including our own, associated MS with moderate changes in the relative amounts of gut microbiota that exacerbate T lymphocyte-mediated inflammation in vitro and in vivo by stimulating pro-inflammatory IFN-γ+ Th1 and inhibiting IL-10+ regulatory T lymphocytes (10, 11). Here, IL10 is linked to myeloid sarcoma.